Navigation Links
TGen drug development teams with Oncoholdings to fight cancer

SCOTTSDALE, Ariz. Jan. 7, 2010 TGen Drug Development (TD2) and Oncoholdings Inc. announced today a partnership agreement that could lead to the prompt development of new anti-cancer agents.

Oncoholdings Inc. is a Syracuse, N.Y.-based pharmaceutical company focused on acquiring and developing the most promising preclinical and early clinical anti-cancer agents. It was founded by some of the world's leading oncology scientists and leverages the unique insights and experiences of its founders and world-class scientific advisory board.

TD2, based in Scottsdale, Ariz., provides drug development firms with expertise in moving promising laboratory discoveries through the pre-clinical, clinical and regulatory approval steps of getting new drugs to patients as quickly and safely as possible.

Under the agreement announced today, TD2 a subsidiary of the Phoenix-based Translational Genomics Research Institute (TGen) will be the exclusive development partner for Oncoholdings' oncology portfolio. The company plans to develop as many as 15 early-stage drugs over the next three years.

"We are extremely eager to put the scientific assets of Oncoholdings on the most expeditious and precise path, moving their drug compounds safely and effectively to benefit cancer patients who so desperately need better treatments," said Dr. Stephen Gately, President of TD2 and a member of the Scientific Advisory Board of Oncoholdings.

Oncoholdings specifically targets drug candidates for development with the potential to:

  • Demonstrate superiority over standard-of-care in pre-clinical or early human trials.
  • Address significant unmet medical needs in oncology.
  • Leverage Oncoholdings' significant expertise in cancer trial design and execution.

"Through our partnership with TGen Drug Development we are confident that we have secured a team comprised of the of the world's top scientists and researchers to develop Oncoholdings' drug portfolio," said Dr. Jeffrey Evans, founder and Chief Executive Officer of Oncoholdings.

"TD2's vast knowledge and experience developing cancer therapies is important to Oncoholdings, as we are positioned to advance more than a dozen compounds with various mechanisms of action. We are very pleased to have found a partner that can meet the challenges of rapidly and effectively progressing our strategy," said Dr. Evans, who also is the former co-founder and President of Rondaxe, a leading pharmaceutical consultancy.

Oncoholdings expects to announce the acquisition of its first group of products in the first quarter of 2011. Among these first products is a novel first-in-class therapy, as well as products with clearly superior efficacy and safety profiles relative to existing therapeutics. Those interested in discussing opportunities with Oncoholdings are encouraged to contact Dr. Evans at:


Contact: Steve Yozwiak
The Translational Genomics Research Institute

Related medicine news :

1. Michael J. Fox Foundation Awards $1 Million to Drive Critical New Research Tools and Technologies in Parkinsons Drug Development
2. Hayes Announces Appointment Of Dr Susan Levine To The Medicare Evidence Development and Coverage Advisory Committee (MEDCAC)
3. Flat Head Syndrome Linked to Developmental Delays
4. Pharmacokinetic/Pharmacodynamic Data Support Further Development of Tobiras Next-Generation CCR5 Receptor Antagonist
5. Chemical tags likely to affect metabolism, cancer development
6. The role of sleep in brain development
7. Talaris Advisors Attracts Veteran Team of Strategic Drug Development Managers
8. Antidepressants in Pregnancy May Delay Developmental Milestones
9. Secretary Clintons Approach to Development: Good Rhetoric, Little Action?
10. Sisters of Charity Health System Welcomes Mark Wiedt to its Business Development Team
11. Avoiding Dairy Due to Lactose Intolerance is Unnecessary in Most Cases and May Pose Diet and Health Risks, Concludes National Institutes of Health Consensus Development Conference Panel
Post Your Comments:
(Date:11/30/2015)... ... ... running, and walking are regular Sunday activities for many South Floridians, but their physical ... That’s when the 7th annual ANF Group Tour de Broward will take place at ... Joe DiMaggio Children’s Hospital. , The community fundraiser, sponsored by ANF Group, consists ...
(Date:11/30/2015)... ... 30, 2015 , ... HemoTreat™ has announced that the company ... to its website. , “Our goal is simple:” says Michael Blasco, HemoTreat’s Chief ... comparison chart and ingredient list allows our customers to quickly see why, and ...
(Date:11/30/2015)... ... 2015 , ... At Grand Dental PC, their priority is to deliver quality ... dental problems, you need to turn to a dentist who listens and responds; an ... a friendly dentist who counsels you on the best ways to maintain and improve ...
(Date:11/30/2015)... ... November 30, 2015 , ... Dr. Seth D. Margulies specializes in ... can visit Dr. Margulies to experience the best available orthodontic experience in the area. ... "NJ Top Dentist"! , Orthodontics is the branch of dentistry that specializes in the ...
(Date:11/30/2015)... ... 2015 , ... International telepathology consultations can significantly improve patient ... Diagnostics researchers. Their review of more than 1,500 pathology cases submitted electronically ... significantly altered treatment plans for more than half of the cases in which ...
Breaking Medicine News(10 mins):
(Date:11/30/2015)... DULLES, Va. , Nov. 30, 2015  IBA ... the manufacture and distribution of radiopharmaceuticals, announced that as ... Zevacor Pharma, Inc. (Zevacor Pharma). The decision to rebrand ... of the firm as well as its close relationship ... owned by Illinois Health and Science (IHS). ...
(Date:11/30/2015)... Nov. 30, 2015 Baxalta Incorporated ... leader dedicated to delivering transformative therapies to ... conditions, today announced the launch and first ... an extended circulating half-life recombinant factor VIII ... full-length ADVATE [Antihemophilic Factor (Recombinant)]. The treatment ...
(Date:11/30/2015)... MOUNTAIN VIEW, Calif. , Nov. 30, ... has been the norm in U.S. medical ... obsolete. The increasingly popular accountable care payer-provider ... payment models and, in their wake, alter ... or quality-based payments will push forward new ...
Breaking Medicine Technology: